Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Tamarack Capital Management’s Ariad Pharmaceuticals, Inc. (ARIA) Holding Carries It To Strong Q3 Gains

Page 1 of 2

Our data culled from the 659 funds in our database which filed 13Fs for the June quarter, and whose portfolios contained at least 5 long positions in companies valued at $1 billion, revealed some startling statistics. Foremost was the fact that an impressive 95% of them delivered positive stock returns with those long positions during the third quarter based on our methodology. In comparison, S&P 500 ETFs returned just 3.3% during the quarter, so that high a percentage of funds posting gains is a noteworthy feat. However, what we don’t see in 13F filings are hedge funds’ holdings that don’t necessarily do as well: the short-side of their portfolios, as well as their low-yield debt positions. Couple that with demanding fees, and you can see why hedge funds consistently underperform the market net of fees, despite being quality stock pickers. That’s why at Insider Monkey, we analyze only the top stock picks of the top hedge funds, to cut through the fees and underperformance. In this article, we’ll take a look at the performance of Justin John Ferayorni‘s Tamarack Capital Management and four of its favorite stocks.

Tamarack Capital’s equity portfolio was valued at $317.91 million on June 30 and consisted of 16 long positions in companies with a market cap of at least $1 billion. Based on the size of those holdings on June 30, those 16 positions delivered weighted average returns of 14% during the third quarter, pushing its year-to-date performance using the same metric to 10.1% gains. It should be noted that our calculations may be different from the fund’s actual returns, as they do not factor in changes to positions during the quarter, or positions that don’t get reported on Form 13Fs, like short positions.

In this article, we’ll take a look at four of the favorite stock picks of Tamarack Capital and see how they performed during the third quarter. As the fund has also now filed its 13F for the September 30 reporting period, we’ll also take a look at how it traded those stocks during the quarter.

First up is NxStage Medical, Inc. (NASDAQ:NXTM), which Tamarack owned 1.2 million shares of at the end of June, valued at $26.01 million. The fund the size of its position in the stock by 29% during the second quarter, taking some profit from the position as shares soared. However, they weren’t done gaining, posting gains of 15.3% during the third quarter, during which time Tamarack trimmed its position by a further 10%, leaving it with 1.08 million shares.

NXTM

At Q2’s end, a total of 27 of the hedge funds tracked by Insider Monkey held long positions in NxStage, a 23% increase quarter-over-quarter. James E. Flynn’s Deerfield Management has the biggest position in NxStage Medical, Inc. (NASDAQ:NXTM), worth close to $97.7 million, comprising 3.8% of its total 13F portfolio. Coming in second is Sectoral Asset Management, led by Jerome Pfund and Michael Sjostrom, holding a $39.6 million position. Other professional money managers with similar optimism include Israel Englander’s Millennium Management and Joseph Edelman’s Perceptive Advisors.

Follow Nxstage Medical Inc. (NASDAQ:NXTM)
Trade (NASDAQ:NXTM) Now!

Next up is Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), in which Tamarack upped its stake by 31% during the second quarter, to 2.1 million shares valued at $15.52 million. Shares of the company returned a stunning 85.3% during the third quarter, which prompted Tamarack to trim its position by 11% to 1.85 million shares. Shares have endured a rough fourth quarter, but are having a great day today, rising by 16%.

Is Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) a great stock to buy now? Money managers believe so, as net ownership of the stock headed up by one to 27. Those funds owned 23.10% of the stock on June 30. Among them, Sarissa Capital Management held the most valuable stake in Ariad Pharmaceuticals, which was worth $95 million at the end of the second quarter. On the second spot was Consonance Capital Management, which amassed $65.4 million worth of shares. Moreover, Camber Capital Management, Point State Capital, and Palo Alto Investors were also bullish on Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA).

Follow Ariad Pharmaceuticals Inc (NASDAQ:ARIA)
Trade (NASDAQ:ARIA) Now!

We’ll check out two more of the fund’s stock picks on the next page.

Page 1 of 2
Loading Comments...